piracetam has been researched along with Critical Illness in 9 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam (LEV) is a broad-spectrum antiepileptic drug with no known interactions and a favorable profile of adverse events." | 2.73 | Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. ( Fuhr, P; Hardmeier, M; Marsch, S; Naegelin, Y; Rüegg, S; Winkler, DT, 2008) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| " This review examines strategies to overcome ARC and summarizes current pharmacokinetic and pharmacodynamic literature in patients with ARC in an effort to provide dosing guidance for this patient population." | 2.52 | Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. ( Daley, MJ; Hobbs, AL; Roberts, KM; Shea, KM, 2015) |
| "Levetiracetam is a first-line therapy for seizures in critically ill patients because of its clinical efficacy, minimal drug interactions, and wide therapeutic window." | 1.42 | Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation. ( Frazee, EN; Kashani, KB; Nei, SD; Wittwer, ED, 2015) |
| "Levetiracetam (LVM) is a novel AED that does not undergo extensive liver metabolism, does not require drug level monitoring, and is not associated with hemodynamic instability." | 1.35 | Safety and efficacy of levetiracetam for critically ill patients with seizures. ( Divertie, GD; Freeman, WD; Nau, KM; Valentino, AK, 2009) |
| "Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0." | 1.34 | Levetiracetam use in critically ill patients. ( Meckler, JM; Privitera, MD; Shutter, LA; Szaflarski, JP; Szaflarski, M; Yates, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalaria, SN | 1 |
| Dahmane, E | 1 |
| Armahizer, M | 1 |
| McCarthy, P | 1 |
| Gopalakrishnan, M | 1 |
| Nei, SD | 1 |
| Wittwer, ED | 1 |
| Kashani, KB | 1 |
| Frazee, EN | 1 |
| Hobbs, AL | 1 |
| Shea, KM | 1 |
| Roberts, KM | 1 |
| Daley, MJ | 1 |
| Smetana, KS | 1 |
| Cook, AM | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| le Noble, JL | 1 |
| Foudraine, NA | 1 |
| Kornips, FH | 1 |
| van Dam, DG | 1 |
| Neef, C | 1 |
| Janssen, PK | 1 |
| Nau, KM | 1 |
| Divertie, GD | 1 |
| Valentino, AK | 1 |
| Freeman, WD | 1 |
| Abend, NS | 1 |
| Monk, HM | 1 |
| Licht, DJ | 1 |
| Dlugos, DJ | 1 |
| Szaflarski, JP | 1 |
| Meckler, JM | 1 |
| Szaflarski, M | 1 |
| Shutter, LA | 1 |
| Privitera, MD | 1 |
| Yates, SL | 1 |
| Rüegg, S | 1 |
| Naegelin, Y | 1 |
| Hardmeier, M | 1 |
| Winkler, DT | 1 |
| Marsch, S | 1 |
| Fuhr, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for piracetam and Critical Illness
| Article | Year |
|---|---|
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Topics: Anti-Bacterial Agents; Creatinine; Critical Illness; Drug Administration Schedule; Humans; Kidney Di | 2015 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
1 trial available for piracetam and Critical Illness
| Article | Year |
|---|---|
Intravenous levetiracetam: treatment experience with the first 50 critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Blood Platelets; Critical Illness; Dose-Response Re | 2008 |
6 other studies available for piracetam and Critical Illness
| Article | Year |
|---|---|
Development and validation of a HPLC-UV assay for quantification of levetiracetam concentrations in critically ill patients undergoing continuous renal replacement therapy.
Topics: Chromatography, High Pressure Liquid; Critical Illness; Drug Stability; Humans; Levetiracetam; Linea | 2018 |
Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation.
Topics: Aged; Anticonvulsants; Critical Illness; Extracorporeal Membrane Oxygenation; Fatal Outcome; Hemofil | 2015 |
Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a Critically Ill Patient and New Dosing Recommendation.
Topics: Aged; Anticonvulsants; Critical Illness; Dose-Response Relationship, Drug; Extracorporeal Circulatio | 2017 |
Safety and efficacy of levetiracetam for critically ill patients with seizures.
Topics: Adult; Aged; Anticonvulsants; Critical Care; Critical Illness; Epilepsy; Female; Humans; Kidney; Lev | 2009 |
Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Critical Illnes | 2009 |
Levetiracetam use in critically ill patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Diseases; Brain Ne | 2007 |